Vaccibody AS is a privately held vaccine company based on the technology conceived and developed at the University of Oslo and Oslo University Hospital in the laboratory of professor Bjarne Bogen, with contributions from professor Inger Sandlie.
Vaccibody AS has developed a unique and innovative vaccine platform with the aim to treat and prevent pre-cancerous diseases or cancer as well as infectious diseases. Through its innovative design Vaccibody’s proprietary vaccine platform generates rapid, durable and broad antibody and T cell responses leading to remarkably potent vaccines.
Vaccibody has developed compelling preclinical data and initiated the first clinical trial with VB10.16, a therapeutic vaccine against cervical precancerous lesion. Also, Vaccibody has initiated development of neoantigen-based individualized cancer vaccines and is using the Vaccibody technology to generate first-in-class therapeutics to treat cancers with a high unmet medical need.